Rapamycin: Here’s the skinny on the anti-aging pill that increases the lifespan—of mice by 10%

The PEARL trial — published in full results in 2025 — was the most rigorous human study of low-dose rapamycin for aging to date. It was a decentralized, single-center, prospective, double-blind, placebo-controlled trial assessing rapamycin in healthy individuals aged 50 to 85 years over one year, registered as NCT04488601 on ClinicalTrials.gov.

What did it find? The honest summary from independent analysis: PEARL showed that low-dose rapamycin is likely safe over a year in healthy adults, with some secondary signals of benefit — particularly in women — but it did not prove that rapamycin extends healthspan or lifespan in humans.

No published human trial has demonstrated lifespan extension with rapamycin. No trial has used all-cause mortality as a primary endpoint in a healthy aging population. That is the central gap between the animal evidence and the human evidence….The off-label prescribing of rapamycin for longevity in healthy adults — which is occurring at scale in longevity medicine practices — is ahead of the evidence.

Related on the SLP

Researchers expanded lifespan of yeast by 80% with a simple genetic tweak. Could this work in humans too? Longevity is increasing: Can we extend our lifespan, one gene at a time?

Viewpoint: The shocking consequences after a year of Robert F. Kennedy Jr.’s distortions, deceptions, and flat-out falsehoods

Retreat from identity labels: Does the sharply declining number of young teens identifying as gay and bisexual reflect an ideological shift?

MAHA moms divided over RFK Jr.’s food‑safety efforts, as recall alerts grow and outbreaks spread

This is an excerpt. Read the original post here